drugset / Trial / NCT07269639
Golcadomide, Poseltinib, and Rituximab for Relapsed/Refractory Diffuse Large B-cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This trial is a proof-of-concept, pilot study, phase I/II clinical trial aimed at generating preliminary data on the combination of golcadomide, poseltinib, and rituximab.
Timeline
- Start
- 2026-01-01
- Primary completion
- 2027-12-01
- Completion
- 2028-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Golcadomide | Other / unclassified | 0.4 mg | — |
| Subject | Poseltinib | Unknown | — | Oral |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |